Algernon Health Inc. (AGNPF)
OTCQB OTCQB Primary 
Algernon Health announces private placement to support Alzheimer's program
Algernon Health (CSE:AGN, OTCQB:AGNPF) announced that it plans to raise up to $500,000 through a non-brokered private placement of units priced at $0.07 each. The proceeds from the financing will be used to advance the company's Alzheimer's disease research program, including preparations to open its first US brain-specific neuroimaging clinic.
Algernon Health bets on the brain: Inside its move into Alzheimer's diagnostics
Christopher Moreau isn't shy about his ambitions. The CEO of Algernon Health (CSE:AGN, OTCQB:AGNPF) wants to build a network of neuroimaging centers across North America, clinics that could help detect Alzheimer's disease earlier, faster, safer, and more comfortably than ever before.
Algernon Pharmaceuticals closes private placement to fund Alzheimer's clinic initiative
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF), a Canadian clinical-stage drug development company, said it has closed the second tranche of a non-brokered private placement, raising total gross proceeds of C$761,000 from the sale of subscription receipts. The financing, first announced on May 27 and updated on June 30, includes C$90,000 from company insiders.
